BioXcel Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022
24 févr. 2022 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop...
BioXcel Therapeutics Announces Journal of the American Medical Association Publication of Data from SERENITY II Pivotal Phase 3 Trial Evaluating BXCL501 in Bipolar Disorders
22 févr. 2022 11h05 HE
|
BioXcel Therapeutics
BXCL501 demonstrated statistically significant and clinically meaningful improvements in primary and key secondary efficacy measures compared with placebo BXCL501 PDUFA Date is April 5, 2022 for...
BioXcel Therapeutics Presents Positive Data from Phase 2 Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2022 ASCO Genitourinary Cancers Symposium
14 févr. 2022 17h00 HE
|
BioXcel Therapeutics
BXCL701 plus KEYTRUDA® (pembrolizumab) demonstrates encouraging composite response rates in SCNC (33%) and adenocarcinoma (21%) cohorts Company plans to continue evaluation of BXCL701 combination as...
BioXcel Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference
09 févr. 2022 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., Feb. 09, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop...
BioXcel Therapeutics Appoints Matt Wiley Chief Commercial Officer
19 janv. 2022 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., Jan. 19, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop...
BioXcel Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
04 janv. 2022 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., Jan. 04, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop...
BioXcel Therapeutics Initiates Pivotal Phase 3 Program of BXCL501 for Acute Treatment of Agitation in Patients with Alzheimer’s Disease
15 déc. 2021 07h00 HE
|
BioXcel Therapeutics
Two Phase 3 studies to enroll a total of 300 patients in assisted living or residential facilities and nursing homes to evaluate the safety and efficacy of BXCL501 Studies designed to maximize...
BioXcel Therapeutics Announces Extension of FDA Review Period of its NDA for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders
01 déc. 2021 07h00 HE
|
BioXcel Therapeutics
PDUFA date extended by three months to April 5, 2022 No Additional Data Requested Following Meeting with FDA NEW HAVEN, Conn., Dec. 01, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq:...
BioXcel Therapeutics to Present at the 2021 Jefferies London Healthcare Conference
11 nov. 2021 07h00 HE
|
BioXcel Therapeutics
NEW HAVEN, Conn., Nov. 11, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop...
BioXcel Therapeutics Reports Third Quarter 2021 Financial Results and Recent Operational Highlights
10 nov. 2021 07h00 HE
|
BioXcel Therapeutics
Plans for commercial and launch readiness advancing for BXCL501 orally dissolving film, for the acute treatment of agitation associated with schizophrenia and bipolar disorders I and II, ahead of...